22 January 2025 – Sydney, Australia | ASX-listed LTR Pharma Limited (ASX:LTP) has announced a strategic partnership with Symbion Pty Ltd, which is one of the largest pharmaceutical wholesalers in Australia. This will facilitate the nationwide distribution of novel nasal spray treatment for Erectile Dysfunction (ED), SPONTAN®.
The non-exclusive agreement, which commences on 1 March 2025, enables LTR Pharma to leverage Symbion's extensive network of over 3,900 pharmacies across the country. This collaboration will play a vital role in supporting the early access scheme that LTR will use and sets a new foundation for SPONTAN’s commercial launch following the appropriate regulatory approval process completion.
Highlights
-
LTR Pharma has signed a non-exclusive agreement to partner with Symbion Pty Ltd, a leading pharmaceutical wholesaler.
-
Symbion’s network includes warehousing, inventory functions, and distribution services that are suited to meet the unique requirements of pharmaceutical products.
-
Operational integration is planned for Q2 2025, which includes:
-
Inventory management systems and integration.
-
Quality control and TGA-compliant product handling protocols for pharmaceutical products.
-
Storage facility setups and maintenance.
-
Development of pharmacist education
-
Development of product support materials.
-
-
The partnership aligns with LTR Pharma’s commitment to delivering rapid and reliable patient access to SPONTAN.
Comments from LTR Pharma Chairman, Lee Rodne: "Partnering with Symbion is a pivotal step in building our commercial infrastructure. Symbion’s extensive distribution network and expertise will ensure seamless access to SPONTAN across Australia. This agreement underscores our commitment to collaboration with industry leaders to establish a reliable supply chain, support the TGA’s early access program, and prepare for SPONTAN’s anticipated commercial launch. Together, we are ensuring the highest standards of pharmaceutical handling and service delivery”
For more information, visit www.ltrpharma.com.
Jane Morgan
Jane Morgan Management
Investor & Media Relations
[email protected]
Peter McLennan
Chief Operating Officer
[email protected]
About us:
About LTR Pharma Limited:
LTR Pharma is focused on improving men’s health, physically and mentally, through the commercialisation of an innovative nasal spray treatment for Erectile Dysfunction. ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships, across multiple age brackets. LTR Pharma’s lead product SPONTAN® is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less. LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.
Contact details:
Jane Morgan
Jane Morgan Management
Investor & Media Relations
[email protected]
